Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Vesprini

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 30, 2008
Improving observer variability in target delineation for gastro-oesophageal cancer--the role of (18F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomographyD Vesprini, Y Ung, R Dinniwell, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 25, 2019
Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancerK Martell, L C Mendez, H Chung, et al.
Clinical and Translational Radiation Oncology|February 6, 2024
Uncovering the armpit of SBRT: An institutional experience with stereotactic radiation of axillary metastasesA Mutsaers, G J Li, J S Fernandes, et al.
British Journal of Cancer|September 16, 1999
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutationsS Wang-Gohrke, W Weikel, H Risch, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 11, 2016
MRI-guided prostate adaptive radiotherapy - A systematic reviewA J McPartlin, X A Li, L E Kershaw, et al.
Cancer Research|July 17, 2001
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive historyT R Rebbeck, Y Wang, P W Kantoff, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 16, 2026
Does Overall Treatment Time Impact Toxicity and Clinical Outcomes After Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy to the Prostate? An evaluation of the Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac RepositoryR L Westley, L A Daamen, F R Teunissen, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 26, 2019
Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective TrialsS Roy, A Loblaw, P Cheung, et al.
Pharmacogenetics|October 23, 2001
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptivesI B Runnebaum, S Wang-Gohrke, D Vesprini, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 30, 2008
Improving observer variability in target delineation for gastro-oesophageal cancer--the role of (18F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomographyD Vesprini, Y Ung, R Dinniwell, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 25, 2019
Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancerK Martell, L C Mendez, H Chung, et al.
Clinical and Translational Radiation Oncology|February 6, 2024
Uncovering the armpit of SBRT: An institutional experience with stereotactic radiation of axillary metastasesA Mutsaers, G J Li, J S Fernandes, et al.
British Journal of Cancer|September 16, 1999
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutationsS Wang-Gohrke, W Weikel, H Risch, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 11, 2016
MRI-guided prostate adaptive radiotherapy - A systematic reviewA J McPartlin, X A Li, L E Kershaw, et al.
Cancer Research|July 17, 2001
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive historyT R Rebbeck, Y Wang, P W Kantoff, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 16, 2026
Does Overall Treatment Time Impact Toxicity and Clinical Outcomes After Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy to the Prostate? An evaluation of the Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac RepositoryR L Westley, L A Daamen, F R Teunissen, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 26, 2019
Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective TrialsS Roy, A Loblaw, P Cheung, et al.
Pharmacogenetics|October 23, 2001
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptivesI B Runnebaum, S Wang-Gohrke, D Vesprini, et al.
Pageof 4